Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development
Members include experts in both clinical research and management of Allergic Bronchopulmonary Aspergillosis and Asthma
LEXINGTON, Mass., July 23, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the formation of the Clinical Advisory Board (CAB) for Pulmazole (PUR1900) – an inhaled iSPERSE™ formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The members of the CAB are world-renowned experts in the fields of both ABPA and asthma and will work closely with Pulmatrix to design and implement future clinical studies of Pulmazole.
"I am very encouraged by the Phase 1 results demonstrating that it is both feasible to administer itraconazole by inhalation and further that high levels of the drug may be achieved within the airways," stated Dr. David Denning, Professor of Infectious Diseases in Global Health and the Director of the National Aspergillosis Centre, Manchester, UK, and co-chair of the Pulmazole CAB. "I believe that Pulmazole has the potential to significantly improve upon both the efficacy and safety profile of oral Sporanox, and I look forward to working with the other members of the advisory board to assist Pulmatrix in advancing the development of Pulmazole to treat patients with fungal asthma, focusing initially on ABPA."
The members of the Pulmazole Clinical Advisory Board are as follows:
David Denning, FRCP, FRCPath, FIDSA, FMedSci - Professor of Infectious Diseases in Global Health; President, Global Action Fund for Fungal Infections; Director, National Aspergillosis Centre, Manchester, UK
Jim Roach, MD, FACP, FCCP – Chief Medical Officer, Pulmatrix
Ritesh Agarwal, MD, DM - Professor of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
William J Calhoun, MD - Professor and Vice Chair for Research, Divisions of Pulmonary, Critical Care and Sleep, and Allergy/Immunology. Department of Medicine at University of Texas Medical Branch, Galveston, TX
Mario Castro, MD, MPH, FCCP - Professor of Medicine, Pediatrics, and Radiology, Division of Pulmonary and Critical Care Medicine at the Washington University School of Medicine in St. Louis, MO
Jonathan Corren, MD - Associate Clinical Professor of Medicine and Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA
Cendrine Godet, MD - Doctor of Infectious Diseases and Pulmonary Medicine at Poitiers University Hospital, France; Coordinator of the French National Board for Chronic Fungal Infection and Secretary of the European CPAnet Board for Chronic Pulmonary Aspergillosis
Richard B. Moss, MD - Professor Emeritus, Pediatrics-Pulmonary Medicine at Stanford University School of Medicine, Stanford, CA
Russell Settipane, MD - Clinical Professor of Medicine at Brown Medical School, Director of the Allergy & Asthma Center, Providence, RI; Associate Editor of Allergy & Asthma Proceedings and the Journal of Precision Respiratory Medicine, President Eastern Allergy and Eastern Pulmonary Conferences
David A. Stevens, MD, FACP, FAAM, FIDSA Professor Emeritus, Infectious Diseases and Geographic Medicine at Stanford University School of Medicine, Stanford, CA; President, California Institute for Medical Research, San Jose, CA
Peter Wark, BMed PhD FRACP FThorSoc - Conjoint Professor, Centre for Healthy Lungs, University of Newcastle & Department of Respiratory and Sleep Medicine John Hunter Hospital, New Lambton NSW, Australia
Michael Wechsler, MD, MMSc - Professor of Medicine, Director, NJH Cohen Family Asthma Institute, Department of Medicine, National Jewish Health, Denver, CO
Additional background on the CAB members can be found on the Pulmatrix website.
"With the successful completion of our Phase 1/1b Pulmazole trial, we are excited to move on to our planned Phase 2 trial in the fourth quarter of this year utilizing a study design informed by the expertise of our Clinical Advisory Board. The insight and expertise provided by our advisors will be critical as we advance the development of Pulmazole in ABPA, and we are honored and extremely fortunate to welcome such distinguished clinicians to the team," stated Jim Roach, MD, Chief Medical Officer of Pulmatrix.
SOURCE Pulmatrix, Inc.